#MCRPC
LightNews LightNews
oncodaily.bsky.social
How Should We Treat mCRPC and HRR Deficiency? - Yüksel Ürün

@yukselurun.bsky.social

oncodaily.com/blog/how-sho...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #mCRPC #HRR #ProstateCancer
Yüksel Ürün: How Should We Treat mCRPC and HRR Deficiency? - OncoDaily
Yüksel Ürün: How Should We Treat mCRPC and HRR Deficiency? / Ankara University School of Medicine, cancer, HRR Deficiency, mCRPC, metastatic
oncodaily.com
August 5, 2025 at 1:43 PM
oncodaily.bsky.social
Longitudinal ctDNA profiling in mCRPC reveals how Tumors evolve - Yüksel Ürün
@yukselurun.bsky.social

oncodaily.com/science/yuks...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ctDNA #mCRPC #ProstateCancer
Yüksel Ürün: Longitudinal ctDNA profiling in mCRPC reveals how Tumors evolve - OncoDaily
Yüksel Ürün: Longitudinal ctDNA profiling in mCRPC reveals how Tumors evolve / Amado J Zurita, Ana M. Aparicio, Ankara University School of Medicine, cancer,
oncodaily.com
May 5, 2025 at 4:59 PM
ascocancer.bsky.social
We issued a new guideline update on systemic therapy in patients with metastatic castration-resistant prostate cancer. #mCRPC

Read more: brnw.ch/21wSrFa
May 6, 2025 at 1:57 PM
yukselurun.bsky.social
PARP inhibitors + hormonal therapy boost OS & PFS in BRCA1/2-mutant & HRR-deficient mCRPC.
🧬Olaparib, Talazoparib, & Rucaparib lead efficacy despite AEs.
@oncoalert.bsky.social
@christianrolfo.bsky.social
@apccc.bsky.social
@asharpmedonc.bsky.social
@weoncologists.bsky.social
January 7, 2025 at 8:01 PM
oncodaily.bsky.social
CONTACT-02 Trial 2025 Update: Atezolizumab Plus Cabozantinib in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CONTACT02 #Atezolizumab #Cabozantinib #ProstateCancer #mCRPC
CONTACT-02 Trial 2025 Update: Atezolizumab Plus Cabozantinib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - OncoDaily
CONTACT-02 trial showed that Atezolizumab plus Cabozantinib improves PFS in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
oncodaily.com
July 3, 2025 at 10:05 PM
onclive.bsky.social
PSMA PET Guides the Individualized Use of Lutetium-Based Therapies in mCRPC @fredhutch.bsky.social #oncology #CRPC
www.onclive.com/view/psma-pe...
PSMA PET Guides the Individualized Use of Lutetium-Based Therapies in mCRPC
Evan Y. Yu, MD, discusses the clinical evolution of radiopharmaceuticals for patients with mCRPC and how PSMA PET may evolve to monitor treatment response.
www.onclive.com
April 22, 2025 at 7:29 PM
ascocancer.bsky.social
Happening Now: Experts explore cutting-edge strategies to personalize treatment for mCRPC in 2025. #ASCO25
June 3, 2025 at 1:02 PM
nimasharifimd.bsky.social
Provocative study from Michael Schweitzer @fredhutch.bsky.social suggesting the activity of EZH2 inhibition in combination with enzalutamide for mCRPC #GU25 @ascocancer.bsky.social @theaacr.bsky.social
February 14, 2025 at 1:36 AM
oncodaily.bsky.social
FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer
@fda.gov

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FDA #Pluvicto #ProstateCancer #mCRPC
April 3, 2025 at 7:41 PM
craigmcrews.bsky.social
Excited to see the Phase 1/2 data on Halda's first oral, RIPTAC targeting mCRPC prostate patients. lnkd.in/e7MYdZvJ
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
October 24, 2025 at 6:13 PM
onclive.bsky.social
Talazoparib in Combination With Enzalutamide Improves OS in mCRPC @ascocancer.bsky.social #GU25

www.onclive.com/view/talazop...
Talazoparib in Combination With Enzalutamide Improves OS in mCRPC
Talazoparib plus enzalutamide demonstrates improved overall survival in metastatic castration-resistant prostate cancer.
www.onclive.com
February 13, 2025 at 3:19 PM
ravimadan.bsky.social
Restaging w/ #PSMA Imaging in #mCRPC #ProstateCancer: When Seeing More Is Detrimental to Care

Sadly a year later this remains true & the frequency of this is 📈

@ascocancer.bsky.social @ascopost.bsky.social

ascopubs.org/doi/pdf/10.1...
August 4, 2025 at 8:05 PM
onclive.bsky.social
Lutetium Lu 177 Vipivotide Tetraxetan Plus Enzalutamide Boosts OS in mCRPC @ascocancer.bsky.social #GU25

www.onclive.com/view/lutetiu...
Lutetium Lu 177 Vipivotide Tetraxetan Plus Enzalutamide Boosts OS in mCRPC
Adding Lu-PSMA-617 to enzalutamide significantly improved overall survival and quality of life in metastatic castration-resistant prostate cancer.
www.onclive.com
February 13, 2025 at 10:04 PM
ascocancer.bsky.social
New from #GU25: Final TALAPRO-2 results reveal a statistically significant & clinically meaningful improvement in survival w/ 1L talazoparib + enzalutamide, both in pts w/ HRR–deficient #mCRPC & in all-comers: dailynews.ascopubs.org/do/final-tal... #ASCODailyNews
February 13, 2025 at 7:25 PM
jco-asco.bsky.social
New @ascocancer.bsky.social mCRPC living guideline updated recommendations for systemic therapy are here! For patients w/ visceral metastases (lung/liver), enzalutamide or docetaxel is advised, regardless of HRR status.

Stay current on mCRPC care: brnw.ch/21wZfuI
January 20, 2026 at 9:47 PM
onclive.bsky.social
Expanded FDA Approval Broadens the Role of Lutetium Lu 177 Vipivotide Tetraxetan in PSMA+ mCRPC @mskcancercenter.bsky.social #PCSM #FDA #ProstateCancer
www.onclive.com/view/expande...
Expanded FDA Approval Broadens the Role of Lutetium Lu 177 Vipivotide Tetraxetan in PSMA+ mCRPC
Michael J. Morris, MD, discusses the FDA expanded approval of lutetium Lu 177 vipivotide tetraxetan in PSMA-positive mCRPC.
www.onclive.com
April 9, 2025 at 8:11 PM
apccc.bsky.social
AR alterations inform circulating tumor DNA detection in metastatic castration resistant #ProstateCancer patients out in Nature Communications
www.nature.com/articles/s41...

Highlights ctDNA positivity as a strong prognostic marker for poor survival in mCRPC, even with AR inhibitor treatments.
December 18, 2024 at 4:13 PM
katesears.bsky.social
First line Metastatic Castration-Resistant Prostate Cancer (mCRPC) from Dr. Fred Saad: myopenmedicine.com/algorithms/f...
First line Metastatic Castration-Resistant Prostate Cancer (mCRPC)
myopenmedicine.com
May 29, 2026 at 4:51 PM
ondankbare-plant.bsky.social
I feel like none of these galaxy brain opinion havers have the slightest clue about disease progression in prostate cancer. Like you can have stable disease for more than a decade with nothing going on, and then bam, it progresses to mCRPC and your 5-year survival rate drops from almost 100% to 28%.
May 18, 2025 at 10:52 PM
onco404.bsky.social
🚨 Testing AKT Inhibition in mCRPC 🤔

📊 Key Results: No Significant Improvement Seen👇

@eortc.org #EJC

#Onco404 #MedSky #OncSky #Cancer #Oncology #ClinicalTrials #PrecisionMedicine #ProstateCancer #mCRPC #Capivasertib #Enzalutamide
April 19, 2025 at 3:51 PM
oncodaily.bsky.social
Five articles suggested by Yüksel Ürün
@yukselurun.bsky.social

oncodaily.com/science/yuks...

#AnkaraUniversity #BRCA #Cancer #FightAgainstCancer #Lenvatinib #mCRPC #mpMRI #OncoDaily #Oncology #Pembrolizumab #ProstateCancer #UrothelialCarcinoma
Five articles suggested by Yüksel Ürün - OncoDaily
Five articles suggested by Yüksel Ürün / Ankara University School of Medicine, BRCA, cancer, Charlie A. Hamm, CLEAR, Elizabeth J.Schafer, fight against
oncodaily.com
December 15, 2024 at 4:56 PM
yukselurun.bsky.social
Congratulations Hatice and the entire team for this impactful study on treatment sequencing in mCRPC!
Important insights for clinical practice!
@oncoalert.bsky.social @apccc.bsky.social @oncbrothers.bsky.social
@mjmorrismd.bsky.social
@drchoueiri.bsky.social

doi.org/10.1016/j.ej...
January 9, 2025 at 1:49 PM
onclive.bsky.social
Talazoparib Plus Enzalutamide Improves rPFS Regardless of AR Alteration Status in mCRPC @theaacr.bsky.social #AACR25 #pcsm #oncology www.onclive.com/view/talazop...
Talazoparib Plus Enzalutamide Improves rPFS Regardless of AR Alteration Status in mCRPC
Talazoparib plus enzalutamide improved rPFS vs placebo plus enzalutamide in patients with mCRPC with or without AR alterations.
www.onclive.com
April 28, 2025 at 12:48 AM
katesears.bsky.social
PSMAfore: Taxane-naive PSMA-positive mCRPC after one prior ARPI progression algorithm from Prof. Karim Fizazi: myopenmedicine.com/algorithms/p...
PSMAfore: Taxane-naive PSMA-positive mCRPC after one prior ARPI progression
myopenmedicine.com
May 22, 2026 at 2:54 PM
shihcheng.bsky.social
Study found advanced mCRPC patients' resistance to ICIs due to diverse immunosuppressive myeloid cells, challenging effective targeting. PMID:39633050, Nature 2025, @Nature https://doi.org/10.1038/s41586-024-08290-3 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
Evolution of myeloid-mediated immunotherapy resistance in prostate cancer | Nature
Patients with advanced metastatic castration-resistant prostate cancer (mCRPC) are refractory to immune checkpoint inhibitors (ICIs)1,2, partly because there are immunosuppressive myeloid cells in tumours3,4. However, the heterogeneity of myeloid cells has made them difficult to target, making blockade of the colony stimulating factor-1 receptor (CSF1R) clinically ineffective. Here we use single-cell profiling on patient biopsies across the disease continuum and find that a distinct population of tumour-associated macrophages with elevated levels of SPP1 transcripts (SPP1hi-TAMs) becomes enriched with the progression of prostate cancer to mCRPC. In syngeneic mouse modelling, an analogous macrophage population suppresses CD8+ T cell activity in vitro and promotes ICI resistance in vivo. Furthermore, Spp1hi-TAMs are not responsive to anti-CSF1R antibody treatment. Pathway analysis identifies adenosine signalling as a potential mechanism for SPP1hi-TAM-mediated immunotherapeutic resistanc
doi.org
March 27, 2025 at 4:10 AM